http://www.wallstreetresearcher.com/Top%20Stock%20TRCH/topstockreporter1.jpg

Todays Trading Alerts

IMAGIN MEDICAL  - IMEXF OTC

Medical Device - Bladder Cancer

New I-Blue Imaging System

FACT SHEET  -  PRESS  - PRESENTATION

This company is on the cutting edge of technology in bladder cancer imaging, detection and monitoring . This device sets a new standard of care for doctors and surgeons in detecting many cancers . We set our initial Target Price on these shares at $0.20. A triple play !

Robert Moriarty Report - Cancer Detection

Imagin Medical Completes Development of i/Blue Alpha B Prototype

2016-12-01 08:00 ET - News Release

Vancouver BC - Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (FRANKFURT: DPD2) (the "Company") announced today that it has completed development of its i/Blue Alpha B Prototype.

The original prototype, developed at the Lawrence Livermore National Laboratory in 2012, was relocated to the University of Rochester, Laboratory of Laser Energetics (LLE) in May 2016 under a Loan Agreement between Imagin Medical and Lawrence Livermore National Laboratory. Dr. Stavros Demos, the inventor of the technology, currently holds the position of Senior Scientist at LLE and is the Technical Scientific Advisor to Imagin Medical. He supported Imagin's development team during the successful retrofitting of the unit with significant improvements to its internal components. Image processing and display software has been developed that integrates state-of-the-art, high resolution cameras and patented, image-blending technology with other proprietary elements. The result will be a composite image highlighting the cancer lesions within the bladder in high definition, estimated to be 100,000 time more sensitive than currently available.

"We're very excited to reach this important milestone," said Dr. Stavros Demos, the inventor of the i/Blue. "It brings us one step closer to our goal of providing better bladder cancer detection and helping to prevent its recurrence."

Clinical trials are scheduled for early 2017. In addition, Imagin is in current negotiations with a product design firm to move i/Blue Imaging System through manufacturing and commercialization.

About Imagin Medical
Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin's initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical.com.

ON BEHALF OF THE BOARD:

Jim Hutchens
 President & CEO

CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

About TopStockReporter.com : 

TopStockReporter.com  , a subsidiary of Target Publishing Inc, and is a leading publisher of todays market and investment news, commentary, proprietary research and videos from seasoned journalists, analysts and contributors covering the financial markets and global economies. Leveraging our extensive distribution network and social media presence, we have cultivated a valuable audience of engaged market enthusiasts, which in turn delivers a variety of unique opportunities for industry partnerships, corporate communications, market exposure and investment. 

A complete disclaimer can be viewed HERE